UPDATE: Citi Upgrades Spark Therapeutics (ONCE) to Buy, Sees M&A Value Upwards of $130/Share

August 7, 2018 11:55 AM EDT
Get Alerts ONCE Hot Sheet
Price: $110.05 --0%

Rating Summary:
    5 Buy, 19 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 13 | New: 72
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

(Updated - August 7, 2018 11:58 AM EDT)

(updated to add analyst comment and price target)

Citi upgraded Spark Therapeutics (NASDAQ: ONCE) from Neutral to Buy, price target $85.00.

Analyst Mohit Bansal comments "While Spark is down ~30% after this AM’s Hemophilia A update, we think this update was incrementally positive and better than our expectations. We would not be too concerned about the immune flare in 2 patients as we think these patients could be managed with prophylactic use of steroids. We note that other gene therapy players are using prophylactic steroids and it was a bit surprising to us that Spark did not use prophylactic steroid in the first place. Nevertheless, the company will employ prophy strategy going forward. We are upgrading the stock to Buy as we think this weakness is a buying opportunity as data in 5/7 patients are better than our expectations & in-line with our doc-checks and we think immune flares can be managed."

The analyst also sees potential value around $130 for the company in a M&A scenario.

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $77.61 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Related Entities

Citi